Every 10-Q that Lunai Bioworks Inc. (RENB) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow RENB and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full RENB filings page.
Lunai Bioworks Inc. reported a small net profit of $1.0 million for the six months ended December 31, 2025, driven mainly by a $12.0 million gain from the bankruptcy and deconsolidation of its Gedi Cube B.V. subsidiary and fair value adjustments, not by core operations.
Operating losses remained significant at $5.1 million over six months, though sharply lower than the prior-year period, and operating cash outflow was $2.4 million. At December 31, 2025, Lunai held only $491,645 in cash against a $19.5 million working capital deficit and a $509.4 million accumulated deficit, resulting in a stockholders’ deficit of $13.5 million.
Management states these conditions raise “substantial doubt” about Lunai’s ability to continue as a going concern and plans to rely on new equity or debt financing, including a November 2025 private placement where only $750,000 of the agreed funding had been received by quarter-end. Subsequent to quarter-end, Nasdaq issued a delisting determination for failure to meet the minimum bid price; Lunai has appealed, but the outcome is uncertain.
Lunai Bioworks Inc. reported a quarterly turnaround to net income of $2.82 million for the three months ended September 30, 2025, versus a $44.21 million loss a year ago. Results were driven by a $12.02 million gain from the bankruptcy and deconsolidation of Gedi Cube B.V., partially offset by a $6.33 million loss on extinguishment of debt and a $0.83 million long‑lived asset impairment.
Operating expenses fell to $3.31 million from $53.34 million, reflecting the absence of last year’s goodwill impairment. Cash was $624,808 and the company disclosed a working capital deficit of $18.92 million, raising substantial doubt about its ability to continue as a going concern. Total liabilities were $20.00 million and stockholders’ deficit was $(13.04) million.
During the quarter, investors converted $16.1 million of new convertible notes into 5.36 million shares at $3.00 per share following a debt exchange. The company also effected a 1‑for‑10 reverse stock split effective September 29, 2025. Common shares outstanding were 23,180,277 at September 30, 2025, and 23,432,391 as of November 10, 2025.